MMMiriam Lobo de Mena

Miriam Lobo de Mena

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Miriam Lobo de Mena has a total of 81 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Epidemiological characterization of biliary tract cancer in a real-world cohort of patients from the Spanish TTD-RETUD gastrointestinal registry

    by T. Macarulla Mercadé, F. Castet, A. Castillo Trujillo, R. Vera García, R. Vidal-Tocino, A. J. Muñoz Martín, P. García Alfonso, A. Fernández Montes, M. Lobo de Mena, R.M. Rodríguez Alonso, et al.

  • Open Access

    Real-world management and outcomes of patients with hepatocellular carcinoma treated with systemic therapy in Spain: a patient cohort from the RETUD gastrointestinal registry

    by Carlos López-López, Eva Martínez de Castro, Ana Fernández Montes, Encarnación Jiménez Orozco, Sandra López Peraita, Ruth Vera, Paula Cerdá, Mariona Calvo, Beatriz García Paredes, Miriam Lobo de Mena, et al.

    Purpose: Characterization of the management and outcomes of patients diagnosed with hepatocellular carcinoma (HCC) and treated with systemic therapy who were included in the Spanish gastrointestinal RETUD registry. Methods/patients: This is a retrospective, registry-based, non-interventional, multicenter study conducted in Spain (NCT06711211, retrospectively registered in Dec-2024). This cohort from the RETUD registry includes adult patients diagnosed with HCC and treated with systemic therapy between Jan-2017 and Feb-2024. Sociodemographic, clinical, therapeutic and survival data are analyzed descriptively. Results: Four hundred and sixty nine patients were included (median age: 65.8 years; 90.2% males; 98.1% Caucasian). At diagnosis, 51.8% presented a clinical stage of Barcelona Clinic Liver Cancer (BCLC)-C. At the start of systemic treatment, 34.5% and 30.3% of the patients showed extrahepatic spread of the disease and main portal vein invasion, respectively. The most frequently administered first-line systemic therapies were sorafenib (57.1%), atezolizumab/bevacizumab (27.7%) and lenvatinib (7.5%). More than a third of the cohort (37.1%) received locoregional treatment at any time (before, concurrent and/or after systemic treatment). Overall, the median progression-free survival (PFS) and overall survival (OS) were 5.1 and 9.8 months, respectively. Patients receiving atezolizumab/bevacizumab showed the longest PFS (10.6 months) and OS (14.0 months) of all treatment groups and a numerically higher objective response rate (ORR) compared to the overall population (31.0% vs 12.5%). Conclusions: This study offers valuable insights into the clinical characteristics, management, and outcomes of HCC patients in Spain in a real-world setting. Our results suggest potential benefits of immunotherapy-based combinations over other available alternatives, supporting findings from interventional and real-world studies.


  • Open Access

    Characterization of thrombosis risk in ambulatory patients with cancer: results of the observational, prospective, multicenter CARTAGO study

    by Javier Trujillo-Santos, Ignacio García-Escobar, Mercedes Salgado, António Araújo, Eva Martínez-De-Castro, Raquel Molina, Victoria E Castellón-Rubio, Pere Domènech, Enrique Gallardo, Esteve Colomé, et al.

    Background: Venous thromboembolism (VTE) is one of the leading causes of death in patients with cancer. Currently, there is a need to develop an easily applicable risk model that can identify patients who will benefit from receiving primary thromboprophylaxis to reduce the incidence of VTE. Patients and methods: This was a non-interventional, multicenter, observational, prospective study carried out in 62 Oncology and Hematology services in Spain and Portugal between January 2018 and December 2019. The main objective of the CARTAGO study was to develop a predictive model within a competitive risk framework to assess the risk of VTE in patients with cancer undergoing chemotherapy, biological, or hormonal treatment. Results: A total of 1596 patients were analyzed. VTE events occurred in 124 (8%) during the 6-month follow-up period (42% of deep vein thrombosis [DVT], 48% of pulmonary embolism [PE], and 10% of both DVT and PE). Four variables were selected for the multivariate predictive model to determine the risk of VTE (tumor type, D-dimer, compression of a vessel by the tumor, and leukocyte count). The 4 variables were associated with an increased risk of VTE (C-statistic, 0.646 [95%CI, 0.620-0.673]). The most significant variables in the internal validation with bootstrapping were the “very high risk” tumors (hazard ratio [HR] 2.032; 95%CI, 1.287-3.211). Conclusion: The CARTAGO model predicts the VTE risk in patients with cancer receiving anticancer therapy in an outpatient setting. This model can easily aid in identifying ambulatory patients who would probably benefit from primary thromboprophylaxis.


  • Open Access

    Relationship between oral microbiota and colorectal cancer: A systematic review

    by Sara Camañes‐Gonzalvo, José María Montiel‐Company, Miriam Lobo‐De‐Mena, María José Safont‐Aguilera, Amaya Fernández‐Diaz, Andrés López‐Roldán, Vanessa Paredes‐Gallardo, Carlos Bellot‐Arcís

    This systematic review aims to investigate the microbial basis underlying the association between oral microbiota and colorectal cancer. A comprehensive search was conducted across four databases, encompassing potentially relevant studies published up to April 2024 related to the PECO question: “Is there a differentiation in oral microbial composition between adult patients diagnosed with colorectal cancer compared to healthy patients?”. The Newcastle‐Ottawa Scale was used to evaluate the quality of the studies included. The level of evidence was assessed through the GRADE (Grading of Recommendations, Assessment, Development and Evaluation) tool. Sixteen studies fulfilled the eligibility criteria. Based on low to moderate evidence profile, high levels of certain subspecies within Firmicutes (such as Streptococcus anginosus , Peptostreptococcus stomatis , S. koreensis , and S. gallolyticus ), Prevotella intermedia , Fusobacterium nucleatum , and Neisseria oralis were found to be associated with colorectal cancer. Conversely, certain bacteria (e.g., Lachnospiraceae , F. periodonticum , and P. melaninogenica ) could exert a symbiotic protective effect against colorectal cancer. Based on existing evidence, it appears that variations in oral microbiota composition exist among individuals with and without colorectal cancer. However, further research is necessary to determine the mechanisms of oral dysbiosis in colorectal carcinogenesis.


  • Evaluation of Breast Cancer Patients with Genetic Risk in a University Hospital: Before and After the Implementation of a Heredofamilial Cancer Unit

    by Miriam Lobo, Sara López‐Tarruella, Soledad Luque, Santiago Lizarraga, Carmen Flores‐Sánchez, Oscar Bueno, Jesús Solera, Yolanda Jerez, Ricardo González del Val, María Isabel Palomero, et al.

    The identification of patients at risk for breast cancer by genetic testing has proven to reduce breast cancer mortality. In 2010, due to a lack of systematization in hereditary cancer assistance in our center, we implemented a multidisciplinary Heredofamilial Cancer Unit (HFCU). We analyze if the HFCU improved the rates of referrals and preventive management of breast cancer patients with genetic risk. We retrospectively compared family history records, referrals of high‐risk patients to genetic counseling, and detection and management of patients with BRCA1/2 mutations in two cohorts of breast cancer patients diagnosed before (first period: 2007–2010) and after the creation of the HFCU (second period: 2010–2013). In the first period, 893 patients were included, and 902 were included in the second. Due to the inability to establish their genetic risk, 142 patients (15.9%) vs. 70 (7.8%) were excluded from analysis (p < 0.001). Among the evaluable patients, 194 (25.8%) vs. 223 (26.8%) fulfilled one or more risk criteria (p = 0.65). Family history documentation in patient's medical records (92.4 vs. 97.8%, p < 0.001) and referral rate (26.3 vs. 52%, p < 0.0001) significantly increased in the second period. Eight BRCA1/2 mutations were detected among patients referred in the first period and 17 among those referred to the HFCU. The rate of preventive surgeries in patients with BRCA mutations significantly increased in the second period (25 vs. 76.5%, p = 0.03). In conclusion, there was a clear improvement in family history records, referrals, and preventive surgeries in breast cancer patients with genetic risk after the implementation of the HFCU.


  • Breast cancer inhibition by statins

    by L. Esserman, M. Campbell, M. Shoemaker, M. Lobo, C. Marx, C. Benz

    1003 Background: Statins are potent cholesterol-lowering drugs with pleiotropic activities including inhibition of Ras, Rac and Rho isoprenylation, altered PI3K/AKT activity and eNOS production, and reduced ubiquinone synthesis. These activities are independent of cholesterol reduction and may explain the prevention of breast cancer and other malignancies seen in a number of studies. Methods: We compared hydrophilic (pravastatin, P) vs. hydrophobic (lovastatin, L; simvastatin, S; fluvastatin, F) statins for their in vitro growth inhibitory effects on a panel of human breast cancer cell lines: MDA-MB-231, SKBR3, BT-474, and MCF-7. To evaluate statin potential to silence expression of specific oncogenes, stable MCF-7 sublines expressing ErbB2 or cyclinD1 promoter-driven luciferase reporters were assayed for growth and promoter activity after statin treatment. Finally, we evaluated the in vivo impact of statin administration in a murine ErbB2 breast cancer model. Results: In vitro results indicate that only ...